-
Chinese ADCs from Escugen, Hansoh, and MediLink Therapeutics Eye Breakthrough Designations in China
•
The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has indicated on its website that three antibody drug conjugates (ADCs) from Chinese pharmaceutical companies are on track to receive breakthrough therapy designations (BTDs) in China. These include Shanghai Escugen’s ESG401, Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692)’s…
-
GSK Commits USD 800 Million to New State-of-the-Art Manufacturing Facility in Pennsylvania
•
GSK plc (NYSE: GSK), a leading UK pharmaceutical company, has announced a significant investment in the United States with the establishment of a multi-purpose facility in Marietta, Pennsylvania. The company will invest USD 800 million to develop a state-of-the-art drug substance manufacturing facility and additional drug product manufacturing capabilities, creating…
-
ImmuneOnco Biopharmaceuticals Partners with Yangtze River Pharmaceutical to Boost Pipeline Development
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a biopharmaceutical company based in China, has entered into a strategic partnership with fellow Chinese firm Yangtze River Pharmaceutical (Group) Co., Ltd. This collaboration aims to strengthen and enhance the development of ImmuneOnco’s investigational pipeline programs. The partnership encompasses a wide range of…
-
LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS
•
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control over LM-302, an antibody drug conjugate (ADC) targeting Claudin 18.2, from US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY). LaNova had previously signed an agreement with Turning Point Therapeutics, Inc. (TPTX.US) in May 2022 to…
-
Zhuhai Beihai Biotech’s Beizary Receives FDA Clearance for Multiple Cancer Indications
•
Zhuhai Beihai Biotech Co., Ltd has announced that it has received marketing clearance from the US Food and Drug Administration (FDA) for its in-house developed drug, Beizary, a modified version of docetaxel, which is indicated for the treatment of various cancers including breast cancer, non-small cell lung cancer, head and…
-
BeiGene’s PD-1 Inhibitor Tevimbra Scores First US Prescription, Offers More Affordable Option
•
BeiGene Ltd, a leading China-based biotechnology company (NASDAQ: BGNE; HKG: 6160; SHA: 688235), has announced the first prescription of its programmed death-1 (PD-1) inhibitor, Tevimbra (tislelizumab), in the United States. This marks a significant milestone for the company as it expands its global reach. Tislelizumab received approval in the US…
-
RemeGen’s Telitacicept Receives Priority Review Status from China’s CDE for gMG Treatment
•
RemeGen (HKG: 9995), a China-based pharmaceutical company, has announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted another market filing for its drug telitacicept with priority review status. The filing seeks approval for the treatment of generalized myasthenia gravis (gMG), a serious…
-
RemeGen’s Taitaxipu Receives CDE Acceptance for New Indication Application in China
•
RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) has announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted a new indication application for its Claudin18.2-targeted antibody, Taitaxipu (Telitacicept), in combination with tislelizumab and chemotherapy as a first-line treatment for advanced gastric cancer. This…
-
Shanghai MicroPort Initiates Pre-Marketing Clinical Study for Embolic Microspheres in Liver Cancer Treatment
•
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical technology company, has announced the commencement of a pre-marketing clinical study for its polyvinyl alcohol embolic microspheres. The company has completed the first pre-marketing clinical implantation in transcatheter arterial chemoembolization (TACE) surgery for left lobe lesions in patients with…
-
Chongqing Zhifei Biological’s Influenza Vaccine Application Accepted by China’s Drug Evaluation Center
•
On October 24, 2024, the Center for Drug Evaluation of the National Medical Products Administration indicated that the influenza virus split vaccine marketing application from Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122)’s wholly-owned subsidiary, Zhifei Longkoma, has been accepted, with the acceptance number CXSS2400114. Currently, Chongqing Zhifei Biological has…
-
TheDerma’s Series A+ Round to Fund R&D and Commercialization of AhR Targeted Drugs
•
TheDerma, a Shanghai-based pharmaceutical company, has announced the completion of a nearly CNY 100 million Series A+ financing round. The round was led by Qingdao Guoxin, with existing shareholders Baino Capital, Han Kang Capital, and Beta Fund continuing to add investments. Kaicheng Capital once again served as the exclusive financial…
-
BMS Launches Cardiac Myosin Inhibitor Camzyos in China for Obstructive Hypertrophic Cardiomyopathy
•
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the official market launch of its cardiac myosin inhibitor Camzyos (mavacamten) in China. The drug is indicated for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM) graded II to III under the New York Heart Association (NYHA) functional classification, aiming to improve…
-
Boston Scientific Reports 19.5% YOY Increase in Q3 Net Sales, Driven by New Product Launches and Market Expansion
•
Boston Scientific Corporation (NYSE: BSX), a leading medical device manufacturer in the U.S., has announced its financial results for the third quarter of 2024, highlighting a robust 19.5% year-on-year (YOY) increase in net sales, which reached USD 4.209 billion. The company’s business units reported significant growth, with MedSurg contributing USD…
-
Hengrui Pharmaceuticals Considers HKEX Secondary Listing Amid Financing Challenges in Mainland China
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, is reportedly planning a secondary listing on the Hong Kong Stock Exchange, according to multiple media sources. The move is anticipated to raise approximately USD 2 billion (RMB 14 billion) and comes amidst concerns regarding “difficulty in financing…
-
Everest Medicines’ Velsipity Approved for Use in Select Hospitals in China’s Greater Bay Area
•
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received approval in the Greater Bay Area (GBA) for its drug Velsipity (etrasimod) to be used in Foshan Fosun Chancheng Hospital and the First Affiliated Hospital of Sun Yat-sen University. These medical institutions are part of the…
-
Daiichi Sankyo’s Pexidartinib Poised for Priority Review in China for TGCT Treatment
•
The official website of the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) has indicated that Daiichi Sankyo (TYO: 4568)’s pexidartinib (PLX3397) is on track to receive priority review status for the treatment of symptomatic giant cell tumor of the tendon sheath (TGCT) in adult patients…
-
AbbVie and Gedeon Richter Expand Partnership to Develop Novel Neuropsychiatric Targets
•
AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced a licensing agreement with Gedeon Richter Plc, aimed at strengthening the development of new potential targets for neuropsychiatric conditions. This collaboration builds upon the nearly two decades of successful partnership on central nervous system (CNS) projects, which…
-
Asieris Pharmaceuticals Gets FDA Green Light for USP1 Inhibitor APL-2302 in Advanced Solid Tumors
•
Asieris Pharmaceuticals (SHA: 688176), a China-based specialist in urogenital cancer treatments, has announced that it has received clinical clearance from the U.S. Food and Drug Administration (FDA) for its in-house developed ubiquitin specific peptidase 1 (USP1) inhibitor, APL-2302, for the treatment of advanced solid tumors. Preclinical studies have indicated that…
-
Henlius Biotech Commences Global Phase III Trial for Serplulimab in First-Line Metastatic Colorectal Cancer
•
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced the dosing of the first patient in a global, multi-center Phase III study for its anti-programmed death-1 (PD-1) inhibitor, HanSiZhuang (serplulimab, HLX10). The study combines serplulimab with bevacizumab and chemotherapy for the first-line treatment of…
-
ImmuneOnco Biopharmaceuticals Initiates Phase Ib Study for Dual-Target Therapy in Systemic Lupus Erythematosus
•
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a Chinese biopharmaceutical company, has announced the first patient in (FPI) for a Phase Ib clinical study of its dual-target macromolecular drug amulirafusp alfa (IMM0306) in the treatment of moderate to severe systemic lupus erythematosus (SLE). This marks a significant advancement in the…
